Summary: Cisplatin-induced ototoxicity, an important dose-limiting side effect, has proven high interindividual variability. Glutathione S-transferases (GSTs) are isoenzymes involved in cellular detoxification processes. Megalin has been demonstrated to bind aminoglycosides, known to be similar to cisplatin for their ototoxicity. The GSTs and megalin expression is genetically polymorphic, which might be responsible for the variability in cisplatin-induced ototoxicity. The genotyping of GSTM1, GSTT1 polymorphisms, and 2 nonsynonymous single nucleotide polymorphisms (SNPs) at megalin genes, rs2075252 and rs2228171, were performed in 68 children diagnosed with solid tumors who received cisplatin-based chemotherapy. After the end of treatment, audiometry demonstrated hearing loss in 79.4% of patients according to Brock classification. The cumulative cisplatin dose >400 mg/m 2 is associated with increased risk of cisplatin-induced ototoxicity [odds ratio (OR), 17.5; 95% confidence interval (CI), 3.09-98.62]. GSTT1 wild genotype and C-allele of rs2228171 SNPs of megalin gene occurred with higher frequency in patients with ototoxicity (P = 0.023; OR, 10; 95% CI, 1.80-56.00 and P = 0.034; OR, 2.67; 95% CI, 1.22-5.82, respectively). In conclusion, our results suggested that GSTT1 wild genotype and C-allele of rs2228171 SNPs might be risk factors for ototoxicity. The cumulative cisplatin dose <400 mg/m 2 should be beneficial in order to ameliorate ototoxicity.
(J Pediatr Hematol Oncol 2013;35:e138-e143) C isplatin [cis-dichlorodiammineplatinum (II)] is an effective chemotherapy for a number of pediatric solid tumors including germ cell tumors, neuroblastoma, hepatoblastoma, and osteosarcoma etc. Its dose-limiting side effects are nephrotoxicity, neurotoxicity, and ototoxicity. Although nephrotoxicity can be successfully reduced by forced diuresis, there is no preventive management available for ototoxicity. The cisplatin-induced ototoxicity is nonreversible, causes bilateral-sensorineural high frequency hearing loss, sometimes associated with a transient or permanent tinnitus. [1] [2] [3] [4] [5] It may be progressive after repeated doses and can occur while patients are receiving chemotherapy 6 and up to 5 years later. The most important clinical outcome of cisplatin-induced ototoxicity, even mild hearing loss, is the risk of considerably delayed speech and language development in children due to impaired recognition of higher frequency consonant sound. 7 The incidence of ototoxicity after cisplatin ranges from 20% to 90% depending on the criteria used. Several risk factors such as cumulative dosage, 8, 9 age <5 years, 8 renal insufficiency, prior cranial irradiation, 10 the combination with other drugs, and high rate of cisplatin administration have been identified as risk factors for cisplatin-induced ototoxicity. 4, 8, [11] [12] [13] Although the influences of nutrition 14 and noise stress 15 are also discussed, no dependent risk factors have been identified to date. Recently published studies showed interindividual susceptibility to cisplatin-induced ototoxicity in both clinical studies and animal tests. 16, 17 Genetic variant of candidate genes have demonstrated an association with toxicity from cisplatin.
Glutathione S-transferases (GSTs), phase II metabolic isoenzymes, play an important role in cell protection by scavenging free radical caused by cisplatin and catalyzing cisplatin by conjugating it with glutathione. GSTs are also expressed in the mammalian cochlear. 18 Two of the most relevant cytosolic GST isoenzymes in biological detoxification processes, GSTT1 and GSTM1, are genetically deleted (null genotype) in a high percentage of human poplation. Although no association of GSTT1 and GSTM1 polymorphisms with cisplatin-induced ototoxicity was demonstrated by Peters et al, 19 Oldenburg et al 20 demonstrated that the presence of GSTM1 wild genotype was a significant risk factor.
Megalin is a multiligand endocytotic receptor, expressed primarily in polarized cells such as the marginal cells of the stria vascularis 21 and the proximal tubular cells of the kidney. 22, 23 Recently, the uptake of aminoglycosides in the proximal tubular cells has also been suggested to be mediated by megalin, [24] [25] [26] known to be similar to cisplatin for their nephrotoxicity and ototoxicity. Thus, the high expression of megalin in the marginal cells of the stria vascularis in the inner ear might play a role in cisplatin-induced ototoxicity.
This study investigated 2 GSTs polymorphisms, GSTT1 and GSTM1, shown to be due to complete deletion of the entire GSTT1 and GSTM1 resulting in null allele, GSTT1*0 and GSTM1*0, respectively. 27, 28 The incidence of deletion polymorphisms of GSTT1 and GSTM1 are reported up to 20% and 50%, respectively, 29 whereas 61.9% and 40.3%, respectively, in Thai population. 30 We investigated 2 reported nonsynonymous single nucleotide
MATERIALS AND METHODS

Patients
We enrolled pediatric patients younger than 15 years of age with a diagnosis of solid tumors, such as fibrosarcoma, germ cell tumor, hepatoblastoma, medulloblastoma, nasopharyngeal carcinoma, neuroblastoma, osteosarcoma, and rhabdomyosarcoma, receiving cisplatin-based chemotherapy between 1997 and 2008 at Ramathibodi Hospital, Bangkok, Thailand. Sixty-eight patients were identified by reviewing medical records and registry of Division of Pediatric Hematology/Oncology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University. The study was approved by the Institutional Review Board at Faculty of Medicine, Ramathibodi Hospital. The basic information about disease, sex, age at treatment, time off treatment, chemotherapy, details of treatment, and, if presented, complications were collected and recorded in data record forms. Signed informed consent was obtained from patients' legal guardians.
The exclusion criteria for participation in the study were patients who had familial risk of hearing impairment and who had renal impairment before therapy, which were considered to be other risk factors for hearing loss.
Audiologic Evaluation
The audiologic examination was performed in all patients after completely treated with cisplatin-based chemotherapy. Otologic evaluations, including visual otoscopic examination, were performed by otolaryngologists before audiologic measurement. If there were diseases of external auditory canals, tympanic membranes, and middle ears, and those that might interfere with audiologic evaluation, patients would receive treatment and followed up until resolution. Subsequently, the tympanometry and conventional audiometry, both bone and air conduction tests, or play audiometry (in young patients) have been used in audiologic evaluation by audiologists on both ears to quantify the change in hearing threshold at 250, 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz.
Classification
To evaluate the severity of acquired hearing loss, the end-of-treatment audiologic results were assigned numeric grades using the classification system of Brock classification 31 (grade 0 to 4) for early detection of cisplatininduced bilateral high frequency hearing loss (Table 1 ). In cases of asymmetric hearing impairment, the numeric grade assigned corresponded to audiologic results from the ear with better hearing. For Brock classification, grades 0 to 4 designate to the severity of hearing impairment. Grade 0 is considered to be normal hearing. Grades 1, 2, 3, and 4 are considered mild, moderate, marked, and severe hearing loss, respectively.
Statistical Analysis
Continuous variables are presented as medians, minimums, and maximums for data with skewed distribution or mean and standard variations for data with normal distributions were calculated to describe the samples. Categorical data are presented as frequencies and percentages. The clinical factors influencing the risk of cisplatin-induced ototoxicity were selected from those commonly used in the literature, including age at treatment, sex, the individual doses, and cumulative doses of cisplatin. Data were analyzed using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL) version 18.0. The associations between hearing loss and the covariates were assessed using analysis of variance and t test for the comparison of the continuous data, and w 2 analyses including Fisher exact test for categorical (nominal) data whenever appropriate. A value of P < 0.05 was accepted as statistically significant. A Bonferroni adjustment was made for multiple comparisons.
In addition, the associations were studied using logistic regression modeling. Unfortunately, the sample size of our study was too small to fit such a model with >1 covariate. Thus, a simplified model with hearing impairment as a binary outcome for adjustment for several covariates was used.
Genotyping
Genomic DNA was isolated from lymphocyte of all patients who participated in this study using Genomic DNA Mini Kit (Geneaid, Taiwan). DNA purification and concentration were determined by NanoDrop 1000 UV/Vis Spectrophotometer (Thermo Fisher Scientific) and frozen at 41C until use. PCR reactions were made up in 25 mL containing 1Â PCR buffer minus Mg + + [20 mM Tris-HCl (pH 8), 50 mM KCl] (Invitrogen), 2 mM of each dNTP (Promaga), 0.25 mM of each primer, 1.5 mM MgCl 2 , 1 U of Taq DNA polymerase (Invitrogen), and 50 ng genomic DNA. PCR amplification parameters were 1 cycle of 5 minutes at 951C, 35 cycles of 1 minute at 951C, 1 minute at 581C, 1 minute at 721C, and finally 1 cycle of 10 minutes at 721C.
The genotype of GSTM1 and GSTT1 were detected by standard multiplex PCR method. GSTM1 and GSTT1 alleles were identified by allele-specific primers:
. GSTM1*0 and GSTT1*0 were determined by the absence of specific GSTM1 and GSTT1 products with 296 bpACTB fragment coamplified as internal control in the PCR reaction, respectively.
The genotype of megalin gene (low-density lipoprotein receptor 2; LRP2; rs2075252 and rs2228171) was performed using the validated genotyping: C__16165996_10_ for rs2075252 and C__3017531_1_ for rs2228171 designated and supplied by Applied Biosystem. The rs2075252 SNPs had caused missense mutation by the exchange of T with 
RESULTS
A total of 68 patients were eligible for the present study and the patients' characteristics are summarized in Table 2 Table 3 summarizes the association of patients' characteristics identified as risk factors in the relevant literatures 4, 8, [11] [12] [13] and hearing impairment thought to be due to cisplatin-induced ototoxicity classified by Brock classification after treatment. Patients were classified into 2 groups, grade 0 and 1 to 4 by Brock classification, according to clinical implication of hearing impairment. The association of hearing impairment and cumulative dose of cisplatin were statistically significant (P = 0.002). Interestingly, all of patients who received cumulative cisplatin dose >600 mg/m 2 developed some degree of hearing impairment after treatment. However, age at diagnosis, sex, intensity of individual dose, cumulative dose of cisplatin, exposure to aminoglycosides, and renal impairment were not found to be statistically significant.
The association of GSTT1, GSTM1 polymorphisms, and grades 0, 1 to 4 cisplatin-induced ototoxicity are shown in Table 4 . We found that GSTT1 wild genotype (GSTT1*1) had a higher frequency in the cisplatin-induced ototoxicity group (69.1%) than the normal hearing group (30.8%). However, no statistical significance was observed in association with GSTM1 polymorphisms and cisplatininduced ototoxicity.
The distribution of rs2075252 and rs2228171 SNPs are also shown in Table 4 . The distribution of C/C, C/T, T/T genotypes of rs2228171 SNPs were not different in both groups. The distribution of C/C + C/T and T/T genotypes of rs2228171 SNPs were also not different between 2 groups (the Fischer exact test, P = 0.206). The C-allele of rs8228171 SNPs in patients with grade 1 to 4 hearing (0.92) occurred at a significantly higher frequency than those with grade 0 hearing (0.86) according to Brock classification at the border of significance [P = 0.034; odds ratio (OR), 4.33; 95% confidence interval (CI), 1.01-18.57]. However, the C-allele frequency in patients with grade 1 to 4 hearing was not significantly different compared with the group of all patients (P = 0.434). No T/T homozygote of rs2228171 SNPs was found in patients with grade 1 to 4 hearing. The allele distributions of rs2075252 SNPs were not significantly different between both groups (grade 0, 1 to 4). All T/T homozygote of rs2075252 SNPs (n = 8) also were C/C homozygote of rs2228171 SNPs.
Two parameters with statistically significant associations were included in the logistic regression model for a multivariable analysis. The 4 independent variables for cumulative cisplatin dose designated to be dichotomous variable, above versus below 400 mg/m 2 , and 2 for GSTT1 wild and null genotype. Patients receiving cumulative doses of cisplatin higher than 400 mg/m 2 had a 17.46-fold increase in the odds of developing high frequency sensorineural hearing loss (P = 0.005; 95% CI, 3.09-98.62) compared with patients receiving lower doses. GSTT1 wild genotype was associated with an increased risk of hearing impairment 
DISCUSSION
The ototoxicity effect remains an important issue that limits clinical application of cisplatin, as no preventive means have been established as standard treatment.
Hearing loss hampers the surviving patient's social integration, academic achievement, and speech and language development. 7 We applied Brock classification 31 in our study because of its correlation among each grade of hearing impairment, losses of critical speech phonemes, and needs of audiologic intervention. The incidence of hearing impairment in our study was higher than several previous studies, which might be due to higher doses of cisplatin 1 who described in 1998 that >50% of patients who received cumulative dose of >400 mg/m 2 had permanent hearing loss. The cumulative cisplatin dose >400 mg/m 2 was considerably an independent risk factor (OR, 17.46) for hearing impairment in our study. In addition, the deteriorative effect on hearing ability was significant when cumulative cisplatin dose reached 600 mg/m 2 . However, the significant risk factors such as young age (especially younger than 5 y of age), 8, 9 cranial irradiation, 10 increased cumulative dose, and individual cisplatin dose 8, 9 in previous literatures had no significant association with ototoxicity in our study.
With regard to our findings of GSTT1, GSTM1 polymorphisms, no significant association was found between GSTM1 polymorphisms and susceptibility to cisplatininduced ototoxicity. However, patients with GSTT1*1 had a 10.05-fold (95% CI, 1.8-56.0) increased risk for cisplatininduced ototoxicity. Peters et al 19 showed no statistically significant association of GSTT1, GSTM1, and GSTP1 polymorphisms with cisplatin-induced ototoxicity. Oldenburg et al 20 found that those with GSTM1*1 had increased risk for cisplatin-induced ototoxicity in cisplatintreated testicular cancer survivors; whereas, GSTT1 polymorphisms were not found to be a significant risk factor. GSTs occupy a key position in biological detoxification processes including antioxidant defense mechanisms. The phylogenetic development of GSTs with enzyme activities overlapping those of the ancestral GSTT1*1 help the living cells to deal with oxidative stress. Recent studies have also shown the effects of GSTTT1*0 and/or GSTM1*0 genotype on pathogenesis of oxidative stress-related diseases such as coronary artery disease, 32,33 asthma, [34] [35] [36] and leukemia. 37, 38 The results of our study are not correlated to hypothesis based on mechanisms of GSTs. As the evolution process had no chance to develop with respect to the toxic effects of chemical compounds that existed in industrialization and modern medicines, genetically deleted GST isoenzymes may play a role in either the toxification or detoxification of man-made chemical or drugs. Ganier et al 39 reported on 2 patients with methylbromide intoxication. One with GSTT1*1 developed very severe neurotoxicity with permanent disability, whereas the other with GSTT1*0 only developed mild and transient neurotoxicity. Thus, the clear explanation of the association between the presence of GSTT1*1 and cisplatin-induced ototoxicity need further investigations including ethnic differences.
In a previous study by Riedemann et al, 40 the A-allele of rs2075252 SNPs were more frequently observed in patients with hearing impairment than those without hearing impairment (OR, 3.45; 95% CI, 1.11-11.2; P < 0.016). No association was found between cisplatin-induced ototoxicity and any allele of rs2228171. We found C-alleles of rs2228171SNPs occurred with significantly higher frequency in patients with ototoxicity (P = 0.034; OR, 4.33; 95%CI, 1.01-18.57) but no intergroup difference was observed with all patients. These results must be interpreted carefully due to the lack of reference data of rs2228171 SNPs frequency as reported recently. However, it indicates that megalin might be involved in the pathogenesis of cisplatin-induced ototoxicity such as in intracellular uptake, endocytosis, and DNA adduct of cisplatin. Further, no association was observed between rs2075252 SNPs and cisplatin-induced ototoxicity in our study.
In conclusion, this is the first pilot study involving incidence and risk factors of cisplatin-induced ototoxicity in Asian pediatric cancer patients. Our case-control association study revealed clinically relevant genetic risk factors for cisplatin-induced ototoxicity by the C-allele of megalin gene rs2228171 SNPs and GSTT1*1; the high cumulative cisplatin dose continued to be an important risk factor. To ameliorate cisplatin-induced ototoxicity, the cumulative cisplatin dose <400 mg/m 2 should be a considerable benefit.
